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Glomerular diseases encompass a broad array of
clinicopathologically defined syndromes which together
account for 90% of end-stage kidney disease costing $20
billion per annum to treat in the United States alone. Recent
insights have defined the central role of the podocyte as both
the regulator of glomerular development as well as the
determinant of progression to glomerulosclerosis. We can
now place all glomerular diseases within this spectrum of
podocytopathies with predictable outcomes based on
podocyte biology impacted by temporal, genetic, and
environmental cues. This simplified construct is particularly
useful to rationalize clinical effort toward podocyte
preservation and prevention of progression as well as to
focus basic research effort on understanding podocyte
biology and for clinical research toward development of
practical monitoring strategies for podocyte injury,
dysfunction, and loss.
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Glomerular diseases account for 90% of end-stage kidney
disease (ESKD) at a cost of $20 billion per year in the US.1
The traditional glomerular disease classification encompasses
a bewildering array of descriptive pathologic entities and
their clinical counterparts. And yet clinical trials and
experience, guided by the hyperfiltration hypothesis of
Brenner et al.,2 tell us that effective blood pressure control,
angiotensin II inhibition, and reduction in proteinuria are
almost uniformly effective in reducing the rate of progres-
sion. This implies that there are common mechanisms
driving disease progression.
Recent identification of mutations causing glomerular
phenotypes, clinical biopsy reports, and experimental model
systems reveal a simplified concept of glomerular diseases in
which podocyte dysfunction, injury, or loss is a common and
determining factor. Toxic, genetic, immune, infectious,
oxidant, metabolic, hemodynamic, and other mechanisms
can all target the podocyte. Depending on the stage of glome-
rular development and associated environmental factors,
podocyte dysfunction, injury, or loss can result in a broad
spectrum of clinical syndromes (Figure 1). Considering
glomerular diseases as being related by these common
podocyte-dependent mechanisms rather than as separate
pathobiological entities facilitates progress towards preven-
tion and treatment. Any national plan aimed at reducing
the cost of health care will need to focus basic scientific effort
on understanding podocyte biology and clinical research
on learning how to prevent and monitor podocyte injury and
depletion as major targets for intervention.
The development and maintenance of normal glomerular
structure and function requires successful signaling and
coordination between all glomerular cells including mesan-
gial, endothelial, parietal epithelial, and visceral epithelial
cells (podocytes). This point is emphasized by the critical
requirement for vascular endothelial growth factor-A pro-
duction by podocytes for normal endothelial and mesangial
cell development and function.3,4 However, the podocyte is
the key organizer of glomerular development and main-
tenance.5,6 This discussion will therefore be focused on the
podocyte.
Figure 2 emphasizes, on the one hand, the key role of the
podocyte in governing glomerular development culminating
in the normal mature glomerulus. On the other, Figure 2 also
depicts the impact of podocyte injury and depletion leading
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ultimately to global glomerulosclerosis. Variations in this
basic pathway are specialized to particular clinical settings
and result in a modified pathologic appearance of the
glomerulus (e.g., diabetic glomerulosclerosis). Nevertheless,
the major sequence of events can conveniently be considered
as a continuum that plays out over time to a greater or lesser
extent in an individual person depending on factors
contributed by genetic and environmental milieus.
GLOMERULAR DEVELOPMENT
Podocytes become recognizable by their expression of key
proteins in the S-shaped stage of nephron development
(Figure 2).5,6 They surround the in-growing blood vessels and
mesenchyme to form a ‘halo’ or ‘head-shaped’ structure. By
this time, podocalyxin is present on the apical surface of
podocytes and tracks the intercellular junctions as they
migrate down the lateral cell surface of the podocyte towards
the developing glomerular basement membrane (GBM).7
During the capillary loop stage of glomerular develop-
ment, there is a major expansion of the GBM requiring
bulk protein synthesis of type IV collagens, laminins, and
glycosaminoglycans.8 At the same time, podocytes begin
forming the interdigitating foot processes that markedly
increases the space between podocytes necessary for efficient
filtration. These foot processes connect the cell to the under-
lying GBM via an intergrin-linked adhesion mechanism.9
The specialized intercellular junctions (slit diaphragms) that
bridge between foot processes are made up of special proteins
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Figure 1 | The spectrum of podocyte diseases. Glomerular diseases
can be considered as a consequence of podocyte dysfunction caused
by genetic and/or environmental factors. Depending on when,
during glomerular development and progression they occur and how
significantly and rapidly they impact the glomerulus the clinical
phenotype will vary. The clinical syndromes associated with podocyte
dysfunction of various types include the following: diffuse mesangial
sclerosis (DMS), congenital nephrotic syndrome of the Finnish type
(CNSF), Alport’s syndrome and variants (Alport þ ), MCD, FSGS,
collapsing glomerulonephropathy (Collapsing GN), immune and
inflammatory glomerulonephropathies (Imm/Inf GN), hypertensive
nephropathy (HTN), diabetic glomerulonephropathy (Diab GN), and
age-associated glomerulonephropathy (Aging). Together these
conditions account for 90% of ESKD.
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Figure 2 | Stages of glomerular development and progression with emphasis on the role of the podocyte. The S-shaped stage.
Developing podocytes acquire podocyte markers during the S-shaped stage of nephron development at which time blood vessels and
mesenchyme invade (arrow). The podocytes (round nuclei) separate from the parietal epithelial cells (triangular nuclei) forming what will
become Bowman’s space. The head-shaped stage: at this stage of glomerular development, the glomerulus consists of a ball of cell surrounded
by developing podocytes. The capillary loop stage: this stage of glomerular development includes the infolding of the surface layer in order to
enlarge the area available for filtration as well as the development of foot processes that interdigitate between podocytes and abut the
underlying GBM which is being synthesized as a collaboration between the podocyte and underlying endothelial and mesangial cells. The
mature glomerulus: the mature glomerulus has maximized filtration surface area by developing intertwining finger-like projections coated by
fenestrated endothelial cells on the inside, a specialized strong thin GBM in the middle, and interdigitating podocyte foot processes connected
by slit diaphragms on the outer surface. Mesangial expansion: loss of some podocytes (20%) is associated with mesangial expansion possibly as
an attempt to reduce the filtration surface area. Adhesion formation: loss of podocytes resulting in appearance of bare areas of filtration surface
results in adhesion of the bare surface to Bowman’s capsule (synechia). Segmental sclerosis: loss of podocytes beyond a critical level results in a
fibrotic glomerular response in that part of the glomerulus (segmental sclerosis). Global sclerosis: loss of podocytes beyond a critical level
results in widespread scarring of that glomerulus (global sclerosis).
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required for the filtration, sensing, and signaling functions
of the podocyte. They include nephrin, podocin, CD2AP,
neph1, fyn, yes, and others.10–15 As the filtration surface of
the mature glomerulus develops in association with an
expanded GBM area, each podocyte has to communicate
with and support its multiple and distant foot processes by
outreach through major and intermediate cell processes that
collectively give rise to the octopus-like shape of the mature
podocyte. The GBM itself is constructed as a thin yet strong
and efficient filtration surface through contributions by the
podocyte, endothelial, and mesangial cells including the
specialized a3, a4, and a5 type IV collagen chains.16
The key organizational signaling systems required to
create and maintain the complex glomerular structure are
not well understood. Master regulatory genes including the
transcription factor WT1 that control programs of down-
stream gene expression are necessary.17–19 As noted above,
coordination between glomerular cells also plays a key role as
demonstrated by the critical requirement for vascular
endothelial growth factor production by podocytes for
normal endothelial and mesangial cell development.3,4
Ultimately, the process of nephrogenesis results in the
production of two kidneys, each containing approximately
1 million nephrons, which collectively filters 100 ml of blood
plasma per minute with high efficiency.
REPLACEMENT OF PODOCYTES AND COMPENSATORY
PODOCYTE HYPERTROPHY
The mature podocyte has limited capacity to divide in
situ.20,21 To what extent podocytes can be replaced at all
during adult life, and if so, how and at what rate, has not yet
been established. One potential mechanism for podocyte
replacement is stem cell immigration from the bone marrow
via blood as has been demonstrated in model systems.22–24 A
second possibility is the migration of cells from the parietal
epithelial cell layer along Bowman’s capsule onto the
glomerular tuft together with a switch to the podocyte
phenotype. In the first case, the stem cell has to traverse the
GBM to home to its destination, whereas in the second case
this is not necessary. A related question is the extent to which
podocytes can hypertrophy to replace lost neighbors or to
compensate for glomerular enlargement. Both human biopsy
analysis as well as animal models show that podocytes can
undergo significant hypertrophy but to a limited extent.25–27
In a model system, as podocytes continue to enlarge they
express different proteins reflecting an ‘adaptation’ stage and
subsequently a ‘decompensation’ stage before becoming lost
from glomeruli.27 Whatever the mechanisms involved in
podocyte hypertrophy and replacement it is possible that they
occur slowly so that podocyte injury leading to podocyto-
penia can become a major threat to the glomerulus.
PROGRESSION TO GLOMERULOSCLEROSIS
The sequence of anatomic events resulting from podocyte
injury has been comprehensively described in multiple
animal model systems by Kriz.20 This includes the appearance
of denuded areas of GBM, adhesion to Bowman’s capsule
(synechia formation), focal segmental glomerulosclerosis,
and global glomerulosclerosis associated with misdirected
filtration into the interstitial compartment contributing to
interstitial injury and fibrosis. The consequences of different
degrees of podocyte loss is exemplified using rat models of
regulated podocyte depletion.28,29 In these models, losso
20% of podocytes causes mesangial expansion alone. Loss of
more then 20% of podocytes leads to the appearance of
denuded areas of GBM resulting in adhesion of the
glomerular capillary loop to Bowman’s capsule (synechia
formation). With 20–40% podocyte loss, selected glomerular
capillary loops become devoid of podocytes and result in a
scarring response limited to that particular loop (segmental
sclerosis). With more than 40% podocyte loss, the glomer-
ulus becomes progressively more sclerotic until at 460%
podocyte loss glomeruli become globally sclerotic and non-
filtering. These stages of podocyte depletion are accompanied
by corresponding degrees of proteinuria and, as an increasing
proportion of glomeruli become involved by measurable
reduction in the clearance function of the kidney.
Glomerular enlargement is also associated with develop-
ment of glomerulosclerosis.30,31 This is true for reduction in
renal mass (nephron number) as well as endocrine conditions
such as acromegaly and obesity in man and in experimental
models of overexpression of growth factors, partial nephrect-
omy, and high calorie intake. The sequence of events flowing
from glomerular enlargement as outlined above is deter-
mined by the limited extent to which podocytes can
hypertrophy to accommodate the increased GBM area to be
served.20,27 Exceeding this capacity appears to lead to
glomerulosclerosis via similar mechanisms to those outlined
for direct podocyte depletion.
THE PODOCYTE DEPLETION HYPOTHESIS
This hypothesis states that whatever the initial insult to the
glomerulus (immune, toxic, infectious, ischemic, etc), the
outcome depends on whether or not the complement of
normal mature podocytes becomes depleted (Figure 3). On
the one hand, if as a result of glomerular injury podocytes are
not depleted, then the glomerulus has the capacity to
remodel and recover essentially normal structure and
function. On the other hand, if significant podocyte
depletion occurs, then the glomerulus (or that part of the
glomerulus) will not recover its normal structure and
function. If progressive podocyte depletion is allowed to
occur over time, then this will be associated with progressive
glomerulosclerosis leading to progressive loss of renal
function culminating in ESKD. Podocyte depletion can occur
as a result of (a) direct podocyte loss because of necrosis,
apoptosis, or detachment; (b) by glomerular enlargement
leading to relative podocyte depletion; or (c) by a switch of
the podocyte phenotype to one which cannot maintain
normal glomerular structure and function.
As outlined above, many potential mechanisms may
trigger podocyte injury and depletion. The loss of some
Kidney International (2007) 71, 1205–1214 1207
RC Wiggins: Spectrum of podocytopathies r e v i e w
podocytes for any reason may trigger a vicious cycle leading
to the loss of more podocytes.32 Angiotensin II may itself
directly amplify this effect,33 thus providing a potential
explanation for the well-known protective effect of angio-
tensin II inhibition in slowing and preventing progression in
glomerular diseases.
THE SPECTRUM OF SYNDROMES ASSOCIATED WITH ALTERED
PODOCYTE BIOLOGY
As indicated by Figure 1 and outlined in sections below,
the different clinical syndromes of glomerular diseases
can each be directly related to various aspects of altered
podocyte biology. These include podocyte developmental
arrest, defective podocyte products, phenotypic switch and
podocyte loss, dedifferentiation, and proliferation.
Arrested glomerular development
Glomerular developmental arrest as a cause of diffuse mesangial
sclerosis. Mutations that result in arrested glomerular
developmental at the ‘head-shaped’ or early capillary loop
stage of glomerular development (Figure 2) cause the clinical
syndrome of diffuse mesangial sclerosis (DMS). Such arrested
glomeruli can still filter to some extent but they leak protein
into the filtrate (nephrotic syndrome) and rapidly progress to
ESKD. The clinical syndrome of DMS includes proteinuria
from birth (congenital nephrotic syndrome) and progression
to ESKD within 6–12 months of age.34,35 The pathologic
appearance of DMS glomeruli includes a halo-shaped
distribution of podocytes surrounding a matrix-containing
glomerular center (‘DMS’), absent foot processes, and lack of
normal glomerular capillary loops.
The recent identification of phospholipase C epsilon
(PLCE1) truncating mutations as a cause of DMS is helpful
for understanding glomerular biology.36 As PLCE1 is expressed
by the podocyte in the developing glomerulus, the fact that
mutations in PLCE1 gene prevent normal glomerular develop-
ment confirms the central role of the podocyte in this process.
Similarly, WT1 is a major podocyte transcription factor present
early in podocyte development, which regulates expression of
key proteins by the podocyte including nephrin and podoca-
lyxin.37,38 Mutations in the WT1 gene also cause DMS.17–19,39
Furthermore, mutations in the b2laminin (LAMB2) gene cause
DMS presumably as a result of defective GBM expansion
and assembly required for normal glomerular development.40,41
The fact that mutations in the above noted genes expressed
by podocytes all cause a similar glomerular phenotype
provides a glimpse of the part of this regulatory machinery
necessary for early stages of glomerular development.
Glomerular developmental arrest as a cause of the congenital
nephrotic syndrome of the Finnish type. Glomerular develop-
mental arrest at the late capillary loop stage of glomerular
development causes massive life-threatening proteinuria as
congenital nephrotic syndrome of the Finnish type. Having
constructed the enormous filtration surface area during the
capillary loop stage of glomerular development, it becomes
necessary that the filtration machine efficiently prevent loss of
blood protein into the filtrate. This goal is achieved in part
through the interdigitating podocyte foot processes and
specialized intercellular junctions (slit diaphragms). By these
mechanisms the podocyte provides physical support to the
GBM to counteract the hydrostatic pressure of blood as well as
supplies special molecules required by the GBM for its normal
structure and function. The foot processes and slit diaphragms
also serve as information mechanisms that signal outside-in to
the podocyte about space between foot processes, pressure,
and similar information required to maintain efficient
filtration. The proteins that make up the slit diaphragm and
its signaling system include nephrin, podocin, neph1, and their
signaling partners fyn, yes, nck, CD2AP, and others.10–15,32–46
Failure to construct normal foot processes and inter-
cellular junctions during development results in massive
proteinuria before and immediately after birth, giving rise to
the syndrome of congenital nephrotic syndrome of the
Finnish type. The major causes of congenital nephrotic
syndrome of the Finnish type in man are mutations in the
NPHS1 gene coding for the slit diaphragm protein nephrin
and in the NPHS2 gene coding for the foot process
membrane protein podocin.42,43 These mutations result in
grossly normal capillary loop development with the key
exception that foot processes and slit diaphragms fail to form
normally. The result is a leaky glomerular filter and
consequent life-threatening loss of protein into the urine.
Defective GBM construction and maintenance (Alport’s
syndrome and variants)
The requirement of the GBM to be strong and rugged yet
thin and discriminating is achieved in part by special type IV
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Figure 3 | The podocyte depletion hypothesis. This hypothesis
states that the outcome for an individual glomerulus will depend on
whether glomerular injury results in significant podocyte depletion or
not. Podocyte ‘depletion’ is considered to be depletion of the
complement of mature podocytes necessary for maintenance of the
normal mature glomerulus. Podocyte ‘depletion’ can therefore occur
by podocyte loss itself, by glomerular enlargement leading to
expansion of GBM area to be served, or by alteration of the podocyte
phenotype such that the podocyte-derived cell is no longer able to
fulfill its normal mature functions, such as occurs in collapsing
glomerulopathy and crescentic nephritis.
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collagen trimers comprised an a3, a4, and a5 chain of type IV
collagen.16 These type IV collagens are produced by the
podocyte and inserted into the GBM during development
and adult life as required for GBM maintenance. Mutations
in the a3 and a4 chains (COL4A3 and COL4A4) can result in
a thin GBM (‘thin GBM disease’). Thin GBM is liable to
rupture causing hematuria, but does not usually cause
progressive loss of renal function or significant proteinuria.47
Rarely, mutations in a3 and a4 type IV collagen genes
(COL4A3 and COL4A4) are associated with progressive loss
of kidney function.48 Mutations in a5 type IV collagen
COL4A5 cause Alport’s syndrome resulting in defects in the
glomerular GBM, the lens of the eye, and the cochlear
membrane. The associated clinical syndrome includes renal
failure, deafness, and visual defects.49 Because the COL4A5
gene is on the X chromosome, Alport’s syndrome is a
sex-linked condition primarily affecting males.
Podocyte phenotypic switch and minimal change disease
In minimal change disease (MCD) podocytes undergo a
phenotypic switch from a cell with foot processes protruding
from its basal surface to a cell without basal processes but
which has acquired microvillus protrusions on its apical cell
surface (‘microvillus transformation’) similar to those present
in renal tubular cells. This remarkable alteration in podocyte
structure is not associated with reduction in expression of key
podocyte proteins such as nephrin or podocin, such as is seen
in forms of focal segmental glomerulosclerosis (FSGS),50,51
although podocyte a-dystroglycan, responsible in part for
adherence of the podocyte to the underlying GBM is reduced
in MCD.52 MCD can therefore be considered as a podocyte
phenotypic switch. It is typically triggered by allergic and
immune events including lymphomas implying that circulat-
ing factors such as cytokines may trigger the switch, possibly
in genetically susceptible individuals.53 This concept is
consistent with the ability of glucocorticoids to rapidly
induce a switch reversal back to the normal podocyte
phenotype, analogous to glucocorticoid being used to
promote maturation (and surfactant production) by alveolar
epithelial cells in the immature lung. The clinical conse-
quence of the ‘switched’ podocyte in MCD is decreased
efficiency of the filtration mechanism with loss of large
amounts of albumin into the glomerular filtrate causing
nephrotic syndrome. Podocytes are not lost into the urine in
MCD with maintenance of the normal podocytes numbers
compatible with the excellent long-term prognosis for renal
function.54
Podocyte depletion from the glomerulus (podocytopenia)
and FSGS
FSGS is a heterogeneous condition that has been recognized
as being associated with podocyte injury for more than
30 years.55,56 The sequence of events by which podocyte
injury results in denudation of GBM, adhesions to Bowman’s
capsule, and progression through segmental to global
sclerosis has been rigorously mapped by Kriz20 and in
numerous experimental reports. Direct quantitative demon-
stration of podocyte loss as a cause of FSGS has been
demonstrated in rat models.28,29 The concept that podocyte
depletion causes FSGS in man is also supported by glome-
rular podocin mRNA being relatively depleted in FSGS
compared with normal glomeruli57 and finding that podo-
cytes are lost into the urine in FSGS.58 These data are
compatible with the hypothesis that FSGS can be caused by
podocyte depletion in man, but whether or not all FSGS in
man is caused by podocyte depletion is not yet established.
For podocytes to serve their function, they must cover the
filtration surface area with foot processes. Glomerular
enlargement is known to be directly associated with develop-
ment of FSGS, and is found in association with obesity,
endocrine conditions such as acromegaly and diabetes, loss of
kidney mass through nephrectomy, chronic glomerulosclero-
sis, and also in glomerulopenia resulting from premature
birth and other causes.30,31,59,60 Quantitative morphologic
data show that FSGS is associated with increased GBM length
per podocyte as further support for the hypothesis that
relative podocyte depletion resulting from glomerular
enlargement can contribute to FSGS.25 Furthermore, in
model systems of glomerular enlargement in rats the
podocyte number did not increase as glomerular volume
increased.27 Rather, compensatory podocyte hypertrophy
occurred up to a threshold point before FSGS supervened,
as would be predicted if relative podocyte depletion was
taking place in the enlarging glomerulus.
Mutations in genes coding for key podocyte proteins also
cause FSGS. Autosomal recessive mutations such as NPHS2
(podocin) and PLCE1 (PLC epsilon non-truncating muta-
tion) cause FSGS in children and young adults.14,36
Autosomal dominant gain of function mutations in genes
coding for a-actinin 4 and TRPC6 cause FSGS in adults.61–65
We do not yet know whether these mutations cause FSGS
through promoting podocyte loss in man or through some
other mechanism. Similarly, experimental deletions of genes
coding for proteins that play a role in podocyte structure and
function causes FSGS in model systems under normal
aging or stressed conditions (reviewed in Mundel et al.,10
Pavenstadt et al.,11 Asanuma and Mundel,12 Ly et al.,13
Antignac,14 and Huber and Benzing15). Transforming growth
factorb overexpression is an example of a model where
podocyte number has been shown to be reduced in asso-
ciation with development of FSGS.66 Circulating factors,67
toxic factors including drugs, oxidants, and deposition of
glycosphingolipids in Fabry’s disease68 and crystallization of
myeloma protein in podocytes69 all cause podocyte injury
leading to FSGS and account in part for the heterogeneity
of this pathologic entity.56
Podocyte dedifferentiation causes ‘collapsing
glomerulopathy’
HIV-associated nephropathy and pamidronate toxicity are
associated with a glomerular phenotype described as
‘collapsing glomerulopathy’ in which the glomerulus loses
Kidney International (2007) 71, 1205–1214 1209
RC Wiggins: Spectrum of podocytopathies r e v i e w
its normal structure including its capillary loops.56,70–73 In
this condition, mature podocyte markers including WT1,
nephrin, podocalyxin, GLEPP1, the cyclin-inhibitors p21,
and p27 and foot processes are lost. In contrast, markers of
immature dividing podocytes are acquired and the podocyte
becomes capable of proliferating. Expression of the HIV
protein nef specifically by podocytes in a transgenic model
system is sufficient to cause this phenotype, thereby
confirming that this is a podocyte disease.70 In the presence
of such dedifferentiated podocytes (absence of normal
mature podocytes), the whole glomerulus can be viewed as
itself dedifferentiating backwards towards a phenotype
resembling the head- or halo-shaped early capillary loop
stage of glomerular development where podocytes are
arranged on the peripheral surface of the glomerular tuft
before capillary loop formation and which is also present in
DMS (Figure 2). Collapsing glomerulopathy is therefore
mechanistically and structurally distinct from other forms of
FSGS. Accumulating data suggest that eradication of the HIV
infection allows podocytes to differentiate back to the mature
phenotype with improvement in the filter characteristics and
preservation of renal function.74
Podocyte injury, loss, and proliferation in immune and
inflammatory glomerulopathies
The outcome in immune and inflammatory glomerulone-
phropathy is strikingly variable even within descriptive
pathologic types. According to the podocyte depletion
hypothesis, whatever the underlying form of immune injury,
those individuals in whom immune injury causes podocyte
loss would develop proteinuria, glomerulosclerosis, and
progressive loss of kidney function, whereas those where
similar injury did not result in podocyte loss would not
develop glomerulosclerosis. For example, in immunoglobulin
A nephropathy biopsy analysis shows a correlation between
podocyte depletion and development of glomerulosclerosis.75
People with active immunoglobulin A nephropathy, systemic
lupus erithematosus, and membranoproliferative glomerulo-
nephritis have increased numbers of podocytes in their
urine,76–79 which can be eliminated by effective treatment.80
Membranous nephropathy is well known to be associated
with podocyte injury owing to insertion of complement
C5b–9 complex into podocyte plasma membranes.81–83 To
what extent the difference between progressive and non-
progressive membranous nephropathy is determined by
whether or not podocytes are lost from glomeruli is not yet
known.
The special case of crescentic nephritis. In crescentic
nephritis, dedifferentiated podocytes in the process of losing
their mature markers can be identified as present in the
glomerular crescent filling Bowman’s space, possibly contri-
buting to podocytopenia via this mechanism.84,85 Quaggin
and co-workers have demonstrated using a transgene model
of Von Hippel–Lindau gene deletion from podocytes that
podocytes themselves can drive the crescentic process in part
via expression of the hypoxia-inducible factor target gene
Cxcr4.86 They also demonstrate that this signaling system is
present in crescentic human glomeruli from patients with
systemic vasculitis. Thus, under certain conditions podocytes
can change their phenotype, proliferate to form at least a part
of the glomerular crescent, and themselves drive the
crescentic process towards a sclerotic outcome.
Hypertensive glomerulosclerosis and the podocyte
There is no doubt that systemic hypertension superimposed
on glomerular disease of any kind leads to more rapid loss
of renal function.87 Blood pressure control and use
of angiotensin-converting enzyme-inhibitors in glomerular
diseases reduces loss of podocytes in the urine.75–77 African
Americans are particularly susceptible to developing ESKD in
association with hypertension and serve as an important
example of hypertension-related kidney failure.88 Low
glomerular number associated with low birth weight cannot
account for this susceptibility, at least in African Americans.89
Biopsy material from adult hypertensive African Americans
shows that about 13% have typical FSGS lesions.90 A large
proportion of the remainder have a focal and global
solidification of the glomerulus described as ‘decompensated
benign nephrosclerosis’.91 Kimmelstiel and Wilson92 and
Helmchen and Wenzel93 noted that the earliest glomerular
changes in this lesion, which they called ‘alterative glome-
rulitis’, was ‘swelling of the epithelial cells of the glomerular
loops’ and that ‘early fibrinous adhesions to the parietal layer
of Bowman’s capsule may be present’. The recent observation
that mutations in WT1 are associated with FSGS in the
African-American population fits in with the general concept
that a podocyte abnormality could play a role.94 African
Americans, like the general hypertensive population, are
protected from progression by angiotensin-converting
enzyme inhibition and effective blood-pressure control.95
To what extent progression to ESKD in different hypertensive
groups can be attributed primarily or secondarily to podocyte
dysfunction/depletion has not yet been determined.
Diabetic glomerulosclerosis as a consequence of glomerular
enlargement and podocyte loss
The concept that podocyte injury is central to progression in
diabetic nephropathy is now well established.96–98 Pathologic
biopsy reports in type I diabetic glomerulosclerosis and type
II diabetic glomerulosclerosis directly link reduced glomer-
ular podocyte number to increased proteinuria99–102 and
show that glomerular podocyte number is the best predictor
of glomerular outcome in type II diabetes in Pima Indians.103
This biopsy data are supported by urine podocyte number
data in man where progressive diabetic glomerulopathy is
associated with increased podocyturia and data showing that
some diabetic treatment strategies reduce podocyturia.104–107
Furthermore, there is extensive experimental data showing
that podocytes injury is an early detectable event after onset
of diabetes as well as reports linking progressive loss of
podocytes to progression of glomerular disease in model
systems.108 Thus, the concept of podocyte loss as a driver of
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the glomerulosclerotic process in diabetes is well documen-
ted. The underlying mechanisms are likely to be in part
related to oxidant injury of the podocyte combined with
glomerular enlargement resulting from insulin and other
growth factors.
High calorie intake, obesity, and glomerulosclerosis
Several experimental models demonstrate that high-calorie
diet results in glomerular enlargement and glomerulosclero-
sis.109–111 This process may be podocyte-dependent as
suggested by analysis of the mechanism for the protective
effect of dietary restriction in rats.27 Obese humans also
develop proteinuria and FSGS,26,56,112 and obesity is an
independent risk factor for progression to ESKD.113,114 The
mechanism by which obesity and high-calorie intake target
the podocyte is not known, but like diabetes is likely to
include glomerular enlargement under the influence of
growth factors and oxidant injury to podocytes.
Aging-associated glomerulopathy
Glomerulosclerosis is closely associated with aging, so that by
over 40 years most individuals have sclerotic glomeruli and
the proportion increases with further aging.115–119 ESKD is
also directly related to aging with a peak incidence of treated
ESKD at 64 years.1 The observed reduction in treated ESKD
above 65 years of age is probably the result of a selection not
to treat ESKD or a failure to recognize ESKD in old age,
particularly in women with small muscle mass and therefore
lower serum creatinine levels. Ninety percent of ESKD is
because of glomerular disease.1 In older age, most of this
ESKD is currently assigned to the category of hypertension
and/or diabetes as a causative mechanism although the
validation of this assignment is not well established, leaving
open the possibility that the aging process itself may
contribute significantly age-associated ESKD by as yet
unrecognized and potentially treatable mechanisms.
In rats, development of glomerulosclerosis occurs in
relation to aging itself.118,119 This process can be accelerated
by high-calorie intake and retarded by calorie restriction in
the absence of either hypertension or diabetes.27 This
tendency to age-related glomerulosclerosis in rats is strain-
dependant, thereby demonstrating that genetic background
also plays a role in age-associated glomerulopathy.
Glomerulosclerosis in the aging rat is a ‘podocyte disease’
as was first pointed out by Floege et al.118 and supported by
recent data.27 The underlying mechanisms will possibly
include alterations in DNA methylation and/or histone
modifications (epigenetic mechanisms) that cause miss-
expression of key genes in the podocyte as well oxidant
injury to mitochondrial DNA and other macromole-
cules.120,121 This would be analogous to other age-associated
diseases that impact key cells which, like podocytes, are
highly differentiated post-mitotic cells with limited capacity
to divide. Examples include neurons in Alzheimer’s and
Parkinson’s disease, pancreatic b cells in diabetes, photo-
receptors in the eye, hair cells in the ear, and conducting cells
in the heart. Age-associated glomerulopathy can therefore be
seen as a senescent process, which sets up the podocyte, and
thereby the whole glomerulus, for failure. This aging process
can be accelerated by a combination of factors including
genetic background, diet, and superimposed conditions such
as hypertension and/or overt diabetes.
PREVENTION AND TREATMENT IMPLICATIONS OF
THE PODOCYTE INJURY/DEPLETION HYPOTHESIS OF
GLOMERULOSCLEROSIS AND PROGRESSION
Podocyte depletion (absolute or relative to glomerular
enlargement) can be considered as the mechanistic explana-
tion underlying the hyperfiltration hypothesis of Brenner
et al.2 that has proved so useful in preventing progression in
the clinic. According to this hypothesis, the primary clinical
focus should be on minimizing factors that tend to promote
injury, podocyte detachment, and depletion. This includes
control of systemic and intraglomerular hypertension and
particularly the use of angiotensin II blockade as a central
element of the prevention strategy. In this sense, reducing
podocyte injury and depletion and reducing proteinuria are
facets of the same strategy. Additional clinical strategies such
as reducing glomerular enlargement and oxidant injury
through calorie restriction, weight control, reduction in
circulating insulin, and other growth factor levels will
probably be confirmed to be clinically important by future
studies. The permissive role of mutations and polymorph-
isms of genes that play a role in the propensity to lose
podocytes in individual patients will need to be defined
and targeted for therapeutic intervention. Measurement of
podocyte products in the urine as a potential mechanism for
monitoring accelerated podocyte loss non-invasively holds
good potential for clinical application. Podocyte replacement
by stem cells may prove to be a useful strategy.
CONCLUSION
A unifying concept, which puts podocytes at the center of
the glomerular disease spectrum, is conceptually simple and
makes intuitive sense to the practicing clinician. It also
reinforces rational clinical and scientific approaches towards
preventing progression.
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